title: Rituximab in the treatment of primary cutaneous B-cell lymphoma: a review.
abstract: Rituximab is a chimeric mouse-human antibody that targets the CD20 antigen, which is found in both normal and neoplastic B cells. In recent years, it has been increasingly used to treat cutaneous B-cell lymphoma and is now considered an alternative to classic treatment (radiotherapy and surgery) of 2 types of indolent lymphoma, namely, primary cutaneous follicle center lymphoma and primary cutaneous marginal zone B-cell lymphoma. Rituximab is also administered as an alternative to polychemotherapy in the treatment of primary cutaneous large B-cell lymphoma, leg type. Its use as an alternative drug led to it being administered intralesionally, with beneficial effects. In the present article, we review the literature published on the use of rituximab to treat primary cutaneous B-cell lymphoma.
authors.affiliation: Servicio de Dermatología, Hospital Central de la Cruz Roja, Universidad Alfonso X El Sabio, Madrid, España. Electronic address: montsefdez@msn.com.
authors.forename: M
authors.initials: M
authors.lastname: Fernández-Guarino
authors.affiliation: Facultad de Medicina, Universidad Complutense, Instituto i+12, Hospital Universitario 12 de Octubre, Madrid, España.
authors.forename: P L
authors.initials: PL
authors.lastname: Ortiz-Romero
authors.affiliation: Servicio de Dermatología, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, España.
authors.forename: R
authors.initials: R
authors.lastname: Fernández-Misa
authors.affiliation: Servicio de Medicina Interna, Hospital Universitario Ramón y Cajal, Madrid, España.
authors.forename: C
authors.initials: C
authors.lastname: Montalbán
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D000069283:Rituximab; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab
keywords: Adverse effects; Efectos secundarios; Follicular lymphoma; Linfoma cutáneo primario difuso de células grandes tipo piernas; Linfoma de la zona marginal; Linfoma folicular; Linfoma primario cutáneo de células B; Marginal zone lymphoma; Primary cutaneous B-cell lymphoma; Primary cutaneous diffuse large B-cell lymphoma leg type; Rituximab